Stacy L Moulder

Stacy L Moulder

UNVERIFIED PROFILE

Are you Stacy L Moulder?   Register this Author

Register author
Stacy L Moulder

Stacy L Moulder

Publications by authors named "Stacy L Moulder"

Are you Stacy L Moulder?   Register this Author

53Publications

1478Reads

10Profile Views

Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1).

Breast Cancer Res Treat 2019 Jul 11;176(1):227-234. Epub 2019 Apr 11.

Division of Cancer Medicine, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-018-05081-zDOI Listing
July 2019

Imaging features of triple-negative breast cancers according to androgen receptor status.

Eur J Radiol 2019 May 21;114:167-174. Epub 2019 Mar 21.

Department of Diagnostic Radiology, Unit 1350, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejrad.2019.03.017DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481318PMC
May 2019

A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β.

Invest New Drugs 2018 12 11;36(6):1103-1109. Epub 2018 Oct 11.

Department of Breast Medical Oncology, Dan L. Duncan Building (CPB5.3542), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1354, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-018-0672-z
Publisher Site
http://dx.doi.org/10.1007/s10637-018-0672-zDOI Listing
December 2018

Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1.

Mol Cell 2018 08;71(4):606-620.e7

Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Graduate School of Biomedical Sciences, University of Texas Health Science Center, Houston, TX 77030, USA; Graduate Institute of Biomedical Sciences and Center for Molecular Medicine, China Medical University, Taichung 404, Taiwan; Department of Biotechnology, Asia University, Taichung 413, Taiwan. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10972765183059
Publisher Site
http://dx.doi.org/10.1016/j.molcel.2018.07.030DOI Listing
August 2018

Development of CNS metastases and survival in patients with inflammatory breast cancer.

Cancer 2018 06 26;124(11):2299-2305. Epub 2018 Mar 26.

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31336DOI Listing
June 2018

Innovative Strategies: Targeting Subtypes in Metastatic Breast Cancer.

Am Soc Clin Oncol Educ Book 2018 May;38:65-77

From the Stanford Comprehensive Cancer, Stanford, CA; The University of Texas MD Anderson Cancer Center, Houston, TX; Mayo Clinic Cancer Center, Rochester, MN.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/EDBK_200715
Publisher Site
http://dx.doi.org/10.1200/EDBK_200715DOI Listing
May 2018

A phase II study of tipifarnib and gemcitabine in metastatic breast cancer.

Invest New Drugs 2018 04 27;36(2):299-306. Epub 2018 Jan 27.

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Dan L. Duncan Building, CPB5.3542, 1515 Holcombe Blvd., Unit 1354, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-018-0564-2
Publisher Site
http://dx.doi.org/10.1007/s10637-018-0564-2DOI Listing
April 2018

Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer.

Clin Cancer Res 2017 Dec 25;23(23):7288-7300. Epub 2017 Sep 25.

Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-17-1544DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5768442PMC
December 2017

Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field.

Oncologist 2017 09 30;22(9):1086-1093. Epub 2017 May 30.

Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

View Article

Download full-text PDF

Source
http://theoncologist.alphamedpress.org/lookup/doi/10.1634/th
Publisher Site
http://dx.doi.org/10.1634/theoncologist.2017-0095DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5599192PMC
September 2017

Adaptive Randomization of Neratinib in Early Breast Cancer.

N Engl J Med 2016 Jul;375(1):11-22

From University of California, San Francisco (J.W.P., C.Y., L.J.V., N.M.H., M.B.B., A.J.C., M.M., J.L., S.E.D., G.L.H., L.J.E.), and QuantumLeap Healthcare Collaborative (M.P.), San Francisco, Buck Institute for Research and Aging, Novato (C.Y.), University of California, Davis, Davis (M.H.), University of California, San Diego, San Diego (A.M.W., R.S., T.H.), and University of Southern California, Los Angeles (D.T.) - all in California; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC (M.C.L., C.I.); University of Minnesota, Minneapolis (D.Y., T.C.H.), and Mayo Clinic, Rochester (J.C.B.) - both in Minnesota; M.D. Anderson Cancer Center, Houston (W.F.S., L.P., S.L.M., D.A.B.), University of Texas Southwestern Medical Center, Dallas (D.M.E., B.B.H.), and Berry Consultants, Austin (A.S., D.A.B.) - all in Texas; Gemini Group, Ann Arbor, MI (J.P.); University of Pennsylvania, Philadelphia (A.D.); Oregon Health and Sciences University, Portland (S.Y.C., K.A.K.); Swedish Medical Center, Seattle (H.G.K.); University of Chicago (R.N.) and Loyola University (K.S.A.) - both in Chicago; Inova Fairfax Hospital, Falls Church, VA (K.K.E.); University of Denver, Denver (A.D.E.); Mayo Clinic, Scottsdale (D.W.N.), and University of Arizona, Tucson (J.E.L., R.K.V.) - both in Arizona; University of Kansas, Lawrence (Q.J.K.); and Emory University, Atlanta (W.C.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1513750DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5259558PMC
July 2016

Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.

N Engl J Med 2016 Jul;375(1):23-34

From University of California, San Francisco (UCSF) (H.S.R., C.Y., L.J.V., M.B.B., N.M.H., A.J.C., C.E., J.L., S.E.D., G.L.H., L.J.E.), and QuantumLeap Healthcare Collaborative (M.P.), San Francisco, Buck Institute for Research and Aging, Novato (C.Y.), University of California, Davis, Davis (M.H.), University of California San Diego, San Diego (A.M.W., R.S.), and University of Southern California, Los Angeles (D.T.) - all in California; University of Chicago (O.I.O., R.N.), and Loyola University (K.S.A.), Chicago; University of Pennsylvania, Philadelphia (A.D.); Gemini Group, Ann Arbor, MI (J.P.); University of Texas M.D. Anderson Cancer Center, Houston (W.F.S., L.P., S.L.M., D.A.B.), UT Southwestern Medical Center, Dallas (D.M.E., B.B.H.), and Berry Consultants, Austin (A.S., D.A.B.) - all in Texas; University of Minnesota, Minneapolis (D.Y.), and Mayo Clinic, Rochester (J.C.B., T.C.H.) - both in Minnesota; Swedish Medical Center, Seattle (H.G.K.); Georgetown Lombardi Comprehensive Cancer Center, Washington, DC (M.C.L., C.I.); University of Kansas, Lawrence (Q.J.K.); University of Arizona, Tucson (J.E.L., R.K.V.), and Mayo Clinic, Scottsdale (D.W.N.) - both in Arizona; Oregon Health and Sciences University, Portland (S.Y.C., K.A.K.); University of Denver, Denver (A.D.E.); Inova Fairfax Hospital, Falls Church, VA (K.K.E.); and Emory University, Atlanta (W.C.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1513749DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5259561PMC
July 2016

Challenges and perspective of drug repurposing strategies in early phase clinical trials.

Oncoscience 2015 30;2(6):576-80. Epub 2015 Jun 30.

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506360PMC
http://dx.doi.org/10.18632/oncoscience.173DOI Listing
August 2015

Multiple gene aberrations and breast cancer: lessons from super-responders.

BMC Cancer 2015 May 29;15:442. Epub 2015 May 29.

Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California at San Diego Moores Cancer Center, La Jolla, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-015-1439-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4446801PMC
May 2015

Leptomeningeal disease and breast cancer: the importance of tumor subtype.

Breast Cancer Res Treat 2014 Aug 20;146(3):477-86. Epub 2014 Jul 20.

Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-014-3054-zDOI Listing
August 2014

A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors.

Invest New Drugs 2013 Aug 20;31(4):918-26. Epub 2012 Nov 20.

Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-012-9898-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482128PMC
August 2013

Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer.

Breast Cancer Res Treat 2013 Jan 15;137(2):631-6. Epub 2012 Dec 15.

Department of Breast Medical Oncology, Unit 1354, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-012-2374-0
Publisher Site
http://dx.doi.org/10.1007/s10549-012-2374-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3867793PMC
January 2013

PIK3CA mutations in advanced cancers: characteristics and outcomes.

Oncotarget 2012 Dec;3(12):1566-75

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681495PMC
http://dx.doi.org/10.18632/oncotarget.716DOI Listing
December 2012

Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel: toxicity, pharmacokinetics, and activity.

Mol Cancer Ther 2011 Jul 13;10(7):1300-7. Epub 2011 May 13.

Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://mct.aacrjournals.org/cgi/doi/10.1158/1535-7163.MCT-11
Publisher Site
http://dx.doi.org/10.1158/1535-7163.MCT-11-0259DOI Listing
July 2011

PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.

Mol Cancer Ther 2011 Mar 7;10(3):558-65. Epub 2011 Jan 7.

Department of Investigational Cancer Therapeutics, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., FC8.2057, Box 0455, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-10-0994DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3072168PMC
March 2011

Does the PI3K pathway play a role in basal breast cancer?

Authors:
Stacy L Moulder

Clin Breast Cancer 2010 Nov;10 Suppl 3:S66-71

Department of Breast Medical Oncology and Phase I Program, The University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CBC.2010.s.014DOI Listing
November 2010

Novel cytotoxic backbones and targeted therapies: recent data and ongoing clinical trials.

Authors:
Stacy L Moulder

Clin Breast Cancer 2010 Sep;10 Suppl 2:S30-40

Department of Breast Medical Oncology and Phase I Program, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CBC.2010.s.010DOI Listing
September 2010

Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer.

Clin Cancer Res 2008 Dec;14(23):7909-16

Department of Breast Medical Oncology, Pathology, Surgical Oncology, Radiation Oncology and Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-08-1104DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4375958PMC
December 2008

Ixabepilone for the treatment of taxane-refractory breast cancer.

Authors:
Stacy L Moulder

Future Oncol 2008 Jun;4(3):333-40

University of Texas, Breast Medical Oncology, Unit 1354, MD Anderson Cancer Center, PO Box 301438, 1155 Pressler Street, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/14796694.4.3.333DOI Listing
June 2008

Adjuvant biologic therapy for breast cancer.

Cancer J 2007 May-Jun;13(3):156-61

Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson, MS, USA.

View Article

Download full-text PDF

Source
https://insights.ovid.com/crossref?an=00130404-200705000-000
Publisher Site
http://dx.doi.org/10.1097/PPO.0b013e318074d80aDOI Listing
January 2008

A phase I open label study of the farnesyltransferase inhibitor CP-609,754 in patients with advanced malignant tumors.

Clin Cancer Res 2004 Nov;10(21):7127-35

Experimental Therapeutics and Phase I Programs, Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-04-0901DOI Listing
November 2004

A Phase I/II Trial of trastuzumab and gefitinib in patients with Metastatic Breast Cancer that overexpresses HER2/neu (ErbB-2).

Clin Breast Cancer 2003 Jun;4(2):142-5

Comprehensive Breast Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

View Article

Download full-text PDF

Source
June 2003

HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer.

Semin Oncol 2002 Jun;29(3 Suppl 11):4-10

Departments of Medicine and Cancer Biology and the Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232-6307, USA.

View Article

Download full-text PDF

Source
June 2002